These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1389 related articles for article (PubMed ID: 26700815)

  • 1. Insulator dysfunction and oncogene activation in IDH mutant gliomas.
    Flavahan WA; Drier Y; Liau BB; Gillespie SM; Venteicher AS; Stemmer-Rachamimov AO; Suvà ML; Bernstein BE
    Nature; 2016 Jan; 529(7584):110-4. PubMed ID: 26700815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bringing IDH into the Fold.
    Zadeh G; Aldape K
    Cancer Cell; 2016 Feb; 29(2):139-40. PubMed ID: 26859452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling epigenetic lesions that cause gliomas.
    Rahme GJ; Javed NM; Puorro KL; Xin S; Hovestadt V; Johnstone SE; Bernstein BE
    Cell; 2023 Aug; 186(17):3674-3685.e14. PubMed ID: 37494934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncometabolite Tinkers with Genome Folding, Boosting Oncogene Expression.
    Ing-Simmons E; Merkenschlager M
    Trends Mol Med; 2016 Mar; 22(3):185-187. PubMed ID: 26856236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of CTCF/cohesin-mediated high-order chromatin structures by DNA methylation downregulates PTGS2 expression.
    Kang JY; Song SH; Yun J; Jeon MS; Kim HP; Han SW; Kim TY
    Oncogene; 2015 Nov; 34(45):5677-84. PubMed ID: 25703332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CNS cancer: Breaking boundaries - IDH mutations in glioma.
    Killock D
    Nat Rev Clin Oncol; 2016 Feb; 13(2):64. PubMed ID: 26787277
    [No Abstract]   [Full Text] [Related]  

  • 7. Partial erosion on under-methylated regions and chromatin reprogramming contribute to oncogene activation in IDH mutant gliomas.
    Wang X; Dai L; Liu Y; Li C; Fan D; Zhou Y; Li P; Kong Q; Su J
    Epigenetics Chromatin; 2023 Apr; 16(1):13. PubMed ID: 37118755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IGFBP2 expression predicts IDH-mutant glioma patient survival.
    Huang LE; Cohen AL; Colman H; Jensen RL; Fults DW; Couldwell WT
    Oncotarget; 2017 Jan; 8(1):191-202. PubMed ID: 27852048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
    Turcan S; Rohle D; Goenka A; Walsh LA; Fang F; Yilmaz E; Campos C; Fabius AW; Lu C; Ward PS; Thompson CB; Kaufman A; Guryanova O; Levine R; Heguy A; Viale A; Morris LG; Huse JT; Mellinghoff IK; Chan TA
    Nature; 2012 Feb; 483(7390):479-83. PubMed ID: 22343889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
    Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTCF-dependent chromatin insulator is linked to epigenetic remodeling.
    Ishihara K; Oshimura M; Nakao M
    Mol Cell; 2006 Sep; 23(5):733-42. PubMed ID: 16949368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs.
    Flavahan WA; Drier Y; Johnstone SE; Hemming ML; Tarjan DR; Hegazi E; Shareef SJ; Javed NM; Raut CP; Eschle BK; Gokhale PC; Hornick JL; Sicinska ET; Demetri GD; Bernstein BE
    Nature; 2019 Nov; 575(7781):229-233. PubMed ID: 31666694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
    Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
    Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IDH mutation impairs histone demethylation and results in a block to cell differentiation.
    Lu C; Ward PS; Kapoor GS; Rohle D; Turcan S; Abdel-Wahab O; Edwards CR; Khanin R; Figueroa ME; Melnick A; Wellen KE; O'Rourke DM; Berger SL; Chan TA; Levine RL; Mellinghoff IK; Thompson CB
    Nature; 2012 Feb; 483(7390):474-8. PubMed ID: 22343901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of the REST transcription factor regulatory networks in IDH mutant and IDH wild-type glioma cell lines and tumors.
    Perycz M; Dabrowski MJ; Jardanowska-Kotuniak M; Roura AJ; Gielniewski B; Stepniak K; Dramiński M; Ciechomska IA; Kaminska B; Wojtas B
    Acta Neuropathol Commun; 2024 May; 12(1):72. PubMed ID: 38711090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
    Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
    Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isocitrate Dehydrogenase Mutations Are Associated with Different Expression and DNA Methylation Patterns of OLIG2 in Adult Gliomas.
    Mo H; Magaki S; Deisch JK; Raghavan R
    J Neuropathol Exp Neurol; 2022 Aug; 81(9):707-716. PubMed ID: 35856894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP.
    Moure CJ; Diplas BH; Chen LH; Yang R; Pirozzi CJ; Wang Z; Spasojevic I; Waitkus MS; He Y; Yan H
    Mol Cancer Res; 2019 Oct; 17(10):2042-2050. PubMed ID: 31292202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.
    Spino M; Kurz SC; Chiriboga L; Serrano J; Zeck B; Sen N; Patel S; Shen G; Vasudevaraja V; Tsirigos A; Suryadevara CM; Frenster JD; Tateishi K; Wakimoto H; Jain R; Riina HA; Nicolaides TP; Sulman EP; Cahill DP; Golfinos JG; Isse K; Saunders LR; Zagzag D; Placantonakis DG; Snuderl M; Chi AS
    Clin Cancer Res; 2019 Feb; 25(4):1261-1271. PubMed ID: 30397180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.